Fig. 1From: Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United StatesAttrition of patients by eligibility criteriaMM multiple myeloma, EHR electronic health record, LOT line of therapy, VRd bortezomib, lenalidomide, and dexamethasone, HSCT hematopoietic stem cell transplantBack to article page